<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848402</url>
  </required_header>
  <id_info>
    <org_study_id>17770</org_study_id>
    <secondary_id>H7K-MC-O005</secondary_id>
    <nct_id>NCT04848402</nct_id>
  </id_info>
  <brief_title>A Device Study in Healthy Participants</brief_title>
  <official_title>A Study to Investigate the Safety and Tolerability of a Wearable On-body Delivery System, and Exploratory Assessment of Participant Response With an Autoinjector, Following Subcutaneous Injections of Placebo in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of two different&#xD;
      devices that may be used to inject medication just under the skin. Participants will receive&#xD;
      placebo; no active drug will be given. The study will last up to five weeks for each&#xD;
      participant, including a one-week overnight stay in the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">December 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Device</measure>
    <time_frame>Baseline through day 7</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>On-Body Delivery System (OBDS)/Multiple Bolus Injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On-Body Delivery System (OBDS)/Multiple bolus injector used to administer placebo subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Auto Injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single auto injector used to administer placebo SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>On-Body Delivery System (OBDS)/Multiple Bolus Injector</intervention_name>
    <description>Used to administer placebo SC.</description>
    <arm_group_label>On-Body Delivery System (OBDS)/Multiple Bolus Injector</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Single Auto Injector</intervention_name>
    <description>Used to administer placebo SC.</description>
    <arm_group_label>Single Auto Injector</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>On-Body Delivery System (OBDS)/Multiple Bolus Injector</arm_group_label>
    <arm_group_label>Single Auto Injector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy male or female participants as determined by medical history,&#xD;
             laboratory tests, physical examination, 12-lead ECGs, and vital signs.&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 18 to 32 kilograms per meter squared (kg/mÂ²)&#xD;
&#xD;
          -  Female participants must not be pregnant, and must test negative for pregnancy&#xD;
&#xD;
          -  Agree to video recording during each administration event using the autoinjector or&#xD;
             bolus injector&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have known allergies to any components of the placebo or related compounds, or history&#xD;
             of significant atopy, or known allergies or irritation to adhesives (e.g. skin&#xD;
             adhesives, band aid)&#xD;
&#xD;
          -  Have an abnormal blood pressure as determined by the investigator&#xD;
&#xD;
          -  Have a history or presence of a bleeding disorder&#xD;
&#xD;
          -  Have a history of any types of neuropathy, radiculopathy, or fibromyalgia that would&#xD;
             affect perception in abdominal wall&#xD;
&#xD;
          -  Have self-perceived dullness or loss-of-sensation on either side of the body or the&#xD;
             abdomen&#xD;
&#xD;
          -  Have any condition that could affect pain perception from an injection&#xD;
&#xD;
          -  Have tattoos or scars over the abdomen, or other factors (eg, rash, excessive folds of&#xD;
             skin) that, in the investigator's opinion, would interfere with injection-site&#xD;
             assessments&#xD;
&#xD;
          -  Have an abnormality in the 12-lead ECG that, in the opinion of the investigator,&#xD;
             increases the risks associated with participating in the trial&#xD;
&#xD;
          -  Are currently using or intend to use painkillers, aspirin, or other nonsteroidal&#xD;
             Anti-inflammatory drugs, anticoagulant or antiaggregant drugs, over-the-counter or&#xD;
             prescription medication for pain or inflammation&#xD;
&#xD;
          -  Have participated, within the last 30 days, in a clinical trial involving an&#xD;
             investigational product. If the previous investigational product has a long half-life,&#xD;
             2 months or 5 half-lives (whichever is longer) should have passed&#xD;
&#xD;
          -  Are unwilling to stop alcohol consumption&#xD;
&#xD;
          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug&#xD;
             screening&#xD;
&#xD;
          -  Are unwilling to abide by the tobacco restrictions&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  Have a pacemaker and/or similar devices/other implantables&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LABCORP</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>44 113 394 5200</phone>
    </contact>
    <investigator>
      <last_name>Hamza Malik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

